Investigational Drug Information for Ripasudil
✉ Email this page to a colleague
What is the development status for investigational drug Ripasudil?
Ripasudil is an investigational drug.
There have been 12 clinical trials for Ripasudil.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 6th 2017.
The most common disease conditions in clinical trials are Fuchs' Endothelial Dystrophy, Corneal Dystrophies, Hereditary, and Cataract. The leading clinical trial sponsors are Kowa Research Institute, Inc., Case Western Reserve University, and Kaiser Permanente.
There are three US patents protecting this investigational drug and sixty-eight international patents.
Summary for Ripasudil
| US Patents | 3 |
| International Patents | 68 |
| US Patent Applications | 113 |
| WIPO Patent Applications | 96 |
| Japanese Patent Applications | 70 |
| Clinical Trial Progress | Phase 3 (2017-12-06) |
| Vendors | 51 |
Recent Clinical Trials for Ripasudil
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) | Kowa Research Institute, Inc. | Phase 3 |
| A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) | Kowa Research Institute, Inc. | Phase 3 |
| Study to Assess Safety and Tolerability of Multiple Doses of EO2002 | Emmecell | Phase 1 |
Clinical Trial Summary for Ripasudil
Top disease conditions for Ripasudil
Top clinical trial sponsors for Ripasudil
US Patents for Ripasudil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ripasudil | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Ripasudil | ⤷ Sign Up | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors | BioAxone BioSciences, Inc. (Cambridge, MA) | ⤷ Sign Up |
| Ripasudil | ⤷ Sign Up | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors | BioAxone BioSciences, Inc. (Boston, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ripasudil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ripasudil | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Ripasudil | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Ripasudil | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Ripasudil | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Ripasudil | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Ripasudil | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| Ripasudil | Japan | JP2019520866 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
